BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor FAQs

On what stock exchange are Bind Therapeutics shares traded, and what is the ticker symbol?

The Bind Therapeutics ticker is BIND and it is traded on the Nasdaq Global Market.

When was Bind Therapeutics's Initial Public Offering?

The company's initial public offering (IPO) priced on September 19, 2013.

Where is Bind Therapeutics's corporate headquarters?

325 Vassar Street, Cambridge, MA 02139

Who are the members of Bind Therapeutics's Board of Directors?

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

Who are the members of the Bind Therapeutics's management team?

You can view our management team by visiting the Management section of our Investor Relations website.

When does Bind Therapeutics's fiscal year end?

31 December

Does Bind Therapeutics pay dividends?

Bind Therapeutics does not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations in our business.

Does Bind Therapeutics have a direct stock purchase plan?

Bind Therapeutics does not currently have a direct stock purchase plan.

Where can I find all of Bind Therapeutics's SEC filings? Where can I download and view quarterly and annual reports?

Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at www.sec.gov.

Do you have another question that hasn't been answered?

Please submit your question using the form below. * Required fields

 
 
 
 
 
 
This helps BIND Therapeutics, Inc. prevent automated submissions.
 

NASDAQ: BIND
Price:
7.55
Change:
- 0.06
Day High:
7.90
Day Low:
7.50
Volume:
358,100
4:00 PM ET on Nov 21, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Gina Nugent
The Yates Network
gina@theyatesnetwork.com

Investor Inquiries
Direct investor inquiries to:
Paul Cox
Stern Investor Relations
212-362-1200
BIND@sternir.com